Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus Osimertinib in Poor Prognostic EGFR-mutated NSCLC
NCT06918782Phase 2Not yet recruiting
- Sponsor
- The University of Hong Kong
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in lung adenocarcinoma, sponsored by The University of Hong Kong. Primary endpoint: Real-world 1-year Progression-Free Survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06918782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918782.